Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy
Abstract:We verified whether early resistance to treatment can be predicted in a subset of patients with very favourable, early stage Hodgkin lymphoma, treated with VBM (vinblastine, bleomycin and methotrexate) chemotherapy and involved-field radiotherapy, an effective combination with very low early and late toxicity. The relative tumour burden (rTB) was volumetrically measured from the staging computed tomography and analysed together with the parameters of pre-therapy evaluation in 61 patients enrolled into the prot… Show more
“…In our study, 56.7% of the participants had relapsed. Therefore, our findings were different compared to earlier studies [25,[26][27][28].…”
Section: Discussioncontrasting
confidence: 99%
“…The study by Sindhu [ 23 ] supported our data and showed that bulk volume was not recognized as a risk factor for HL. Many hospitals utilize low-dose radiation on patients who have refractory or partial responses to chemotherapy to lower the risk of subsequent cancers [ 26 ]. Patients in our research received radiation at a rate of 11.6%, thus results from our investigation are very much similar to other studies.…”
Objectives: This study aimed to determine the impact of prognostic markers on the outcomes of Hodgkin lymphoma.
Methods: It is a cross-sectional, single-center study. A total of 60 patients diagnosed with Hodgkin lymphoma were recruited for the study over five years between 2016 to 2020. The study setting was the National Institute of Blood and Bone Marrow Transplant in Pakistan. The Statistical Package for Social Sciences (SPSS) version 23 (IBM Corp., Armonk, NY, USA) was used for statistical analysis.
Results: In the study population, 63.3% of the patients were male (38/60), and 36.7% were female (22/60). Hodgkin lymphoma was divided into four stages: stage I (18.3%), stage II (18.3%), stage III (46.7%), and stage IV (16.7%). Patients in stage III had a higher value of hemoglobin (Hb) than in other stages of the disease. The erythrocyte sedimentation rate was high in 56.7% of stage III patients than in patients of the other stages. The lactate dehydrogenase (LDH) levels were not under the normal range in 51.6% of patients. Only 20% of patients in stage III had LDH values within the normal range, whereas 26.6% did not.
Conclusion: There was a significant impact of prognostic factors on the survival of patients with Hodgkin lymphoma.
“…In our study, 56.7% of the participants had relapsed. Therefore, our findings were different compared to earlier studies [25,[26][27][28].…”
Section: Discussioncontrasting
confidence: 99%
“…The study by Sindhu [ 23 ] supported our data and showed that bulk volume was not recognized as a risk factor for HL. Many hospitals utilize low-dose radiation on patients who have refractory or partial responses to chemotherapy to lower the risk of subsequent cancers [ 26 ]. Patients in our research received radiation at a rate of 11.6%, thus results from our investigation are very much similar to other studies.…”
Objectives: This study aimed to determine the impact of prognostic markers on the outcomes of Hodgkin lymphoma.
Methods: It is a cross-sectional, single-center study. A total of 60 patients diagnosed with Hodgkin lymphoma were recruited for the study over five years between 2016 to 2020. The study setting was the National Institute of Blood and Bone Marrow Transplant in Pakistan. The Statistical Package for Social Sciences (SPSS) version 23 (IBM Corp., Armonk, NY, USA) was used for statistical analysis.
Results: In the study population, 63.3% of the patients were male (38/60), and 36.7% were female (22/60). Hodgkin lymphoma was divided into four stages: stage I (18.3%), stage II (18.3%), stage III (46.7%), and stage IV (16.7%). Patients in stage III had a higher value of hemoglobin (Hb) than in other stages of the disease. The erythrocyte sedimentation rate was high in 56.7% of stage III patients than in patients of the other stages. The lactate dehydrogenase (LDH) levels were not under the normal range in 51.6% of patients. Only 20% of patients in stage III had LDH values within the normal range, whereas 26.6% did not.
Conclusion: There was a significant impact of prognostic factors on the survival of patients with Hodgkin lymphoma.
“…Предприняты разработки по созданию статистических моделей, в которые помимо объема опухолевого поражения включен и вариант лечебной программы. При анализе четырех групп пациентов, получивших схему полихимиотерапии BEACOPP с ЛТ при распространенных стадиях (n =107) [30], ABVD с ЛТ в тех же режимах (n =117), ABVD с ЛТ при всех стадиях (n =129) [31] и VBM (винбластин, блеомицин, метотрексат) с ЛТ в группе с благоприятным течением (n=61) [32], выяснили, что наиболее значимым фактором прогноза для риска развития первичной резистентности был именно объем опухоли. Несмотря на различия в лечебных программах, во всех группах отмечена существенная прямая корреляция между объемом поражения и вероятностью резистентности заболевания.…”
Section: объем опухолевого поражения как предиктивный фактор прогнозаunclassified
Today approximately 70% of patients with Hodgkin lymphoma can be cured with the combined-modality therapy. Tumor burden, the importance of which was demonstrated 15 years ago for the first time, is a powerful prognostic factor. Data of literature of representations on predictive value of Hodgkin's lymphoma tumor burden are shown in the article. The difficult immunological relations between tumor cells and reactive ones lead to development of the main symptoms. Nevertheless, the collective sign of tumor burden shows the greatest influence on survival and on probability of resistance, which relative risk can be predicted on this variable and treatment program. Patients with bulky disease need escalated therapy with high-dose chemotherapy. Integration into predictive models of the variable will change an expected contribution of clinical and laboratory parameters in the regression analyses constructed on patients with Hodgkin's lymphoma. Today the role of diagnostic functional methods, in particular a positron emission tomography, for metabolic active measurement is conducted which allows excluding a reactive component.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.